Yeah, so one of the main things is to have an earlier sort of readout. So rather than waiting for the classical endpoint of overall survival, really, is there anything that tells us earlier whether this particular investigational agent, et cetera, is going to work? And so what we’re hoping to do, I mean, firstly, we do need to validate it in the external cohort...
Yeah, so one of the main things is to have an earlier sort of readout. So rather than waiting for the classical endpoint of overall survival, really, is there anything that tells us earlier whether this particular investigational agent, et cetera, is going to work? And so what we’re hoping to do, I mean, firstly, we do need to validate it in the external cohort. So we are collaborating with, you know, a larger sort of trials collaborative group to validate this because we need to ensure that this can be applicable across the board. But if that’s the case, then we can look at six month PF status. And then if there is a readout at that point, that could potentially be used as a surrogate for overall survival. So I think that’s really promising.
